IP Library › Granted Patent US 12,215,347
Granted Patent B2
US 12,215,347 · App. 17/381,693 · Granted Feb 4, 2025

Chimeric antigen receptors with enhanced signaling and activities and uses thereof

Inventors: Michael Thomas Bethune (Castro Valley, CA); Yi Zhang (Foster City, CA); Thomas John Van Blarcom (Oakland, CA); Siler Panowski (Barkeley, CA); Barbra Johnson Sasu (San Francisco, CA)
Assignee: Allogene Therapeutics, Inc.
C12N5/0636A61K39/4611A61K39/4631A61K39/464402C07K14/7051C12N15/86A61K2239/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,215,347
App. No.
17/381,693
Granted
Feb 4, 2025
Kind
B2
Abstract

Provided herein are recombinant antigen receptors, for example chimeric antigen receptors (CARs), that comprise modified cytoplasmic domains that provide improved signalling and thereby provide improved performance and safety. Also provided are polynucleotides encoding the recombinant antigen receptors, vectors comprising the polynucleotides, and engineered immune cells comprising the vectors and/or polynucleotides. The invention further provides methods for engineering immune cells to express the recombinant antigen receptors. Improved recombinant antigen receptor signalling is also provided by co-expressing a first recombinant antigen receptor and a second recombinant antigen receptor or co-expressing a recombinant antigen receptor and a protein involved in transducing the signal from the activated recombinant antigen receptor. Also provided are methods of treating a variety of conditions, including, but not limited to, blood cancers and cancers characterized by solid tumors, by administering the engineered cells to patients suffering from such a condition.

Claims (13)

1. A recombinant antigen receptor comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular domain that comprises a co-stimulatory domain and an ITAM-containing domain, wherein

the ITAM-containing domain comprises from N-terminus to C-terminus (a) CD3z1 ITAM, CD3d ITAM, CD3z2 ITAM, CD3e ITAM, CD3z3 ITAM, CD3g ITAM, (b) CD3z1 (YAEL (SEQ ID NO: 152)) ITAM, CD3z2 (YAEL (SEQ ID NO: 152)) ITAM, CD3z3 (YAGL (SEQ ID NO: 153)) ITAM, or (c) CD3z1 (YAEL (SEQ ID NO: 152)) ITAM, CD3d (YAPL (SEQ ID NO: 154)) ITAM, CD3z2 (YAEL (SEQ ID NO: 152)) ITAM, CD3e (YAPI (SEQ ID NO: 155)) ITAM, CD3z3 (YAGL (SEQ ID NO: 153)) ITAM, CD3g (YAPL (SEQ ID NO: 154)) ITAM.

2. The recombinant antigen receptor of claim 1 , wherein the recombinant antigen receptor is a chimeric antigen receptor (CAR).

3. The recombinant antigen receptor of claim 1 , wherein the antigen binding domain comprises a heavy chain variable domain (VH) and a light chain variable domain (VL).

4. The recombinant antigen receptor of claim 1 , wherein the co-stimulatory domain comprises 4-1BB co-stimulatory domain.

5. The recombinant antigen receptor of claim 1 , wherein the intracellular domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 35 and 37.

6. The recombinant antigen receptor of claim 5 , wherein the intracellular domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30 and 37.

7. The recombinant antigen receptor of claim 5 , wherein the intracellular domain comprises an amino acid sequence of SEQ ID NO:35.

8. A polynucleotide comprising a DNA sequence encoding the recombinant antigen receptor of claim 1 .

9. A vector comprising the polynucleotide of claim 8 .

10. An engineered immune cell comprising the recombinant antigen receptor according to claim 1 .

11. A pharmaceutical composition comprising the engineered immune cell of claim 10 .

12. A recombinant antigen receptor comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular domain, wherein the intracellular domain comprises a 4-1BB co-stimulatory domain, a CD3z ITAM-containing domain, and further comprises an additional Lck recruiting motif (LRM), wherein the additional LRM is a CD8 LRM, and wherein the CD8 LRM comprises, consists of or consists essentially of the amino acid sequence of SEQ ID NO: 56.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2026
From: BETHUNE, MICHAEL THOMAS; ZHANG, YI; VAN BLARCOM, THOMAS JOHN; PANOWSKI, SILER; SASU, BARBRA JOHNSON
To: ALLOGENE THERAPEUTICS, INC.
Reel/Frame 075072/0883 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2026
From: BETHUNE, MICHAEL THOMAS; ZHANG, YI; VAN BLARCOM, THOMAS JOHN; PANOWSKI, SILER; SASU, BARBRA JOHNSON
To: ALLOGENE THERAPEUTICS, INC.
Reel/Frame 075073/0048 →
Continuity (3)
Provisional Application 63219710 · Jul 8, 2021
Provisional Application 63054701 · Jul 21, 2020
Related Publication 20220023346A1 · Jan 27, 2022
References Cited (115)
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 4683202A · Mullis · 1987 [cited by applicant]
US 4754065A · Levenson et al. · 1988 [cited by applicant]
US 4800159A · Mullis et al. · 1989 [cited by applicant]
US 4975278A · Senter et al. · 1990 [cited by applicant]
US 5037743A · Welch et al. · 1991 [cited by applicant]
US 5143830A · Holland et al. · 1992 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surami et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5661016A · Loneberg · 1997 [cited by applicant]
US 5750373A · Garrard et al. · 1998 [cited by applicant]
US 5858358A · June et al. · 1999 [cited by applicant]
US 5883223A · Gray et al. · 1999 [cited by applicant]
US 6352694B1 · June et al. · 2002 [cited by applicant]
US 6534055B1 · June et al. · 2003 [cited by applicant]
US 6692964B1 · June et al. · 2004 [cited by applicant]
US 6797514B2 · Brenson et al. · 2004 [cited by applicant]
US 6867041B2 · Berenson et al. · 2005 [cited by applicant]
US 6887466B2 · June et al. · 2005 [cited by applicant]
US 6905680B2 · June et al. · 2005 [cited by applicant]
US 6905681B1 · June et al. · 2005 [cited by applicant]
US 6905874B2 · Berenson et al. · 2005 [cited by applicant]
US 7067318B2 · June et al. · 2006 [cited by applicant]
US 7144575B2 · June et al. · 2006 [cited by applicant]
US 7172869B2 · June et al. · 2007 [cited by applicant]
US 7175843B2 · June et al. · 2007 [cited by applicant]
US 7232566B2 · June et al. · 2007 [cited by applicant]
US 20060121005A1 · Berenson et al. · 2006 [cited by applicant]
US 20190002521A1 · Maher · 2019 [cited by examiner]
US 20190365875A1 · Brander et al. · 2019 [cited by applicant]
US 20200048618A1 · Cordoba · 2020 [cited by examiner]
US 20210107979A1 · Zhang · 2021 [cited by examiner]
WO WO2012058458A2 · 2012 [cited by applicant]
WO WO2013153391A1 · 2013 [cited by applicant]
WO WO2014039523A1 · 2014 [cited by applicant]
WO WO2014184143A1 · 2014 [cited by applicant]
WO WO2014184741A1 · 2014 [cited by applicant]
WO WO2014184744A1 · 2014 [cited by applicant]
WO WO2014191128A1 · 2014 [cited by applicant]
WO WO2018208849A1 · 2018 [cited by examiner]
WO WO2019165116A1 · 2019 [cited by examiner]
WO WO2019210081A2 · 2019 [cited by applicant]
WO WO2020078925A1 · 2020 [cited by examiner]
WO WO2020180591A1 · 2020 [cited by applicant]
WO WO2020180664A1 · 2020 [cited by applicant]
WO WO2020180694A1 · 2020 [cited by applicant]
WO WO2021041806A1 · 2021 [cited by applicant]
WO WO2020068702A1 · 2021 [cited by applicant]
WO WO2022020456A2 · 2022 [cited by applicant]
Palacios, E., Weiss, A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23, 7990-8000 (2004). (Year: 2004). [cited by examiner]
Huston, J. S.; Levinson, D.; Mudgett-Hunter, M.; Tai, M. S.; Novotný, J.; Margolies, M. N.; Crea, R. (1988). Proceedings of the National Academy of Sciences of the United States of America. 85 (16): 5879-5883.) (Year: 1… [cited by examiner]
Perlmutter, R.M., Marth, J.D., Lewis, D.B., Peet, R., Ziegler,S.F. and Wilson, C.B. Structure and expression of Ick transcripts in human lymphoid cells). Journal J. Cell. Biochem. 38 (2), 117-126 (1988) (Year: 1988). [cited by examiner]
Genseq database search result for WO2019165116-A1, matching Sequence 59 of present application. (Year: 2019). [cited by examiner]
Abate-Daga, Daniel , et al., “CAR models: next-generation CAR modifications for enhanced T-cell function”, Mol Ther Oncolytics; May 18, 2016;3:16014. doi: 10.1038/mto.2016.14. eCollection 2016. [cited by applicant]
Al-Lazikani, Bissan , et al., “Standard Conformations for the Canonical Structures of Immunoglobulins”, J. Mol. Biol. (1997) 273, 927-948. [cited by applicant]
Bettini, Matthew L., et al., “CD3 ITAM diversity is required for optimal T cell receptor signaling and thymocyte development”, J Immunol. Sep. 1, 2017; 199(5): 1555-1560, doi: 10.4049/jimmunol.1700069. [cited by applicant]
Bird, Robert E., et al., “Single Chain Antigen-Binding Proteins”, Science, vol. 242, Issue 4877, Oct. 21, 1988; DOI: 10.1126/science.3140379. [cited by applicant]
Boerner, P , et al., “Production of Antigen-Specific Human Monoclonal Antibodies From in Vitro-Primed Human Splenocytes”, J Immunol 1991; 147:86-95; http://www.jimmunol.org/content/147/1/86. [cited by applicant]
Brenner, Malcom K., et al., “Adoptive T Cell Therapy of Cancer”, Curr Opin Immunol. Apr. 2010 ; 22(2): 251-257. doi:10.1016/j.coi.2010.01.020. [cited by applicant]
Capel, Peter J.A., et al., “Heterogeneity of Human IgG Fc Receptors”, Immunomethods 4, 25-34 (1994). [cited by applicant]
Chothia, Cyrus , et al., “Structural Repertoire of the Human VH Segments”, J. Mol. Biol. (1992) 227, 799-917. [cited by applicant]
Cole, S. P.C., et al., “The EBV-Hybridoma Technique and Its Application to Human Lung Cancer”, Monoclonal Antibodies and Cancer Therapy pp. 77-96 1985, Alan R. Liss, Inc. [cited by applicant]
Davenport, A. J., et al., “Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity”, Proc Natl Acad Sci U S A. Feb. 27, 2018;115(9):E2068-E2076. doi: 10.1073/pnas.171626… [cited by applicant]
Dayhoff, M. O., “A model of evolutionary change in proteins—Matrices for detecting distant relationships”, Atlas of Protein sequence and structure, pp. 345-352, 1978. [cited by applicant]
De Haas, Masja , et al., “Fc gamma receptors of phagocytes”, J Lab Clin Med; Oct. 1995; 126(4):330-41. [cited by applicant]
EPO , “International Search Report & Written Opinion”, mailed on Feb. 4, 2022 for PCT/US2021/042555. [cited by applicant]
Eshhar, Zelig , et al., “Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell r… [cited by applicant]
Fellouse, F. A., “High-throughput Generation of Synthetic Antibodies from Highly Functional Minimalist Phage-displayed Libraries”, J. Mol. Biol.; 2007; 373; 924-940. [cited by applicant]
Feucht, Judith , et al., “Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency”, Nat Med. Jan. 2019 ; 25(1): 82-88. doi: 10.1038/s41591-018-0290-5. [cited by applicant]
Gait, M. J., “Oligonucleotide Synthesis: A Practical Approach”, IRL Press Ltd., Oxford, England, 1984 (TOC). [cited by applicant]
Genbank , accession No. CR541888.1 [cited by applicant]
Genbank , accession No. AAA53133 4-1BB [cited by applicant]
Genbank , accession No. AY358337.1, [cited by applicant]
Genbank , accession No. NP_006130.1, T-cell-specific surface glycoprotein CD28 isoform 1 precursor, [cited by applicant]
Genbank , accession No. CR542051.1, [cited by applicant]
Genbank , accession No. NM001166664.1, [cited by applicant]
Genbank , accession No. NM-022153.1, [cited by applicant]
Genbank , accession No. NM-173799.4, [cited by applicant]
Genbank , accession No. NM-181780.3, [cited by applicant]
Genbank , accession No. NPP_001139345.1, T-cell surface glycoprotein CD8 alpha chain isoform 1 precurse ( [cited by applicant]
Gudipati, Venugopal , et al., “Inefficient CAR-proximal signaling blunts antigen sensitivity”, Nature Immunology; 21, 848-856 (2020). https://doi.org/10.1038/s41590-020-0719-0. [cited by applicant]
Guyer, Ruth , et al., “Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors”, The Journal of Immunology; vol. 117, No. 2, Aug. 1976. [cited by applicant]
Hartl, Frederike A., et al., “Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function”, Nat Immunol; Aug. 2020;21(8):902-913. doi: 10.1038/s41590-020-0732-3. Epub Jul. 20, 2020. [cited by applicant]
Hoogenboom, Hennie R., et al., “By-passing Immunisation Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro”, J. Mol. Hid. (1!)92) 227. 381-:388. [cited by applicant]
Jayasena, S. D., et al., “Aptamers: an emerging class of molecules that rival antibodies in diagnostics”, Clin Chem. Sep. 1999;45(9):1628-50. [cited by applicant]
Kabat, Elvin A., et al., “Sequences of Proteins of Immunological Interest”, 5th Ed. NIH publication, No. 91-3242; 1992 (TOC). [cited by applicant]
Kim, Jin-Kyoo , et al., “Localization of the site of the murine IgG1 molecule that is invoiced in binding to the murine Intestinal Fc receptor”, Eur. J. Immunol. 1994. 24: 2429-2434. [cited by applicant]
Köhler, G. , et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature, vol. 256, 1975, 495-497. [cited by applicant]
Sadelain, Michel , et al., “The promise and potential pitfalls of chimeric antigen receptors”, Current Opinion in Immunology 2009, 21:215-223. [cited by applicant]
Li, Lunyi , et al., “Ionic CD3-Lck interaction regulates the initiation of T-cell receptor signaling”, PNAS Jul. 18, 2017 114 (29) E5891-E5899; first published Jun. 28, 2017; https://doi.org/10.1073/pnas.1701990114. [cited by applicant]
Liu, Haiyan , et al., “On the dynamics of TCR:CD3 complex cell surface expression and downmodulation”, Immunity; .Nov. 2000;13(5):665-75. doi: 10.1016/s1074-7613(00)00066-2. [cited by applicant]
MacCallum, Robert M., et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography”, J. Mol. Biol. (1996) 262, 732-745. [cited by applicant]
Majzner, Robbie G., et al., “Tuning the Antigen Density Requirement for CAR T-cell Activity”, Cancer Discov.; May 2020;10(5):702-723. doi: 10.1158/2159-8290.CD-19-0945. Epub Mar. 19, 2020. [cited by applicant]
Makabe, Koki , et al., “Thermodynamic Consequences of Mutations in Vernier Zone Residues of a Humanized Anti-human Epidermal Growth Factor Receptor Murine Antibody, 528”, The Journal of Biological Chemistry vol. 283, No… [cited by applicant]
Marks, James D., et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage”, J. Mol. Biol. (1991) 222, 581-597. [cited by applicant]
McCafferty, John , et al., “Phage antibodies: filamentous phage displaying antibody variable domains”, Nature vol. 348, pp. 552-554 (1990). [cited by applicant]
Mukhopadhyay, Himadri , et al., “Systems Model of T Cell Receptor Proximal Signaling Reveals Emergent Ultrasensitivity”, PLoS Comput Biol 9(3):2013; e1003004. doi: 10.1371/journal.pcbi.1003004. [cited by applicant]
Payne, Gillian , “Progress in immunoconjugate cancer therapeutics”, Pipeline, Cancer Cell, vol. 3, pp. 207-212, (2003). [cited by applicant]
Purbhoo, Marco A., et al., “T cell killing does not require the formation of a stable mature immunological synapse”, Nature Immunology; vol. 5, No. 5, 2004, 524-530. [cited by applicant]
Ravtech, Jefferey V., et al., “Fc Receptors”, Annu. Rec. Immunol. 1991 9:457-92. [cited by applicant]
Remington , “The Science and Practice of Pharmacy”, 21st Ed. Mack Publishing, 2005, Table of Contents. [cited by applicant]
Rosenberg, Steven A., et al., “Adoptive cell transfer: a clinical path to effective cancer immunotherapy”, Nat Rev Cancer. Apr. 2008 ; 8(4): 299-308. doi:10.1038/nrc2355. [cited by applicant]
Sambrook, J. , et al., “Molecular Cloning: A Laboratory Manual”, Second Ed., Cold Spring Harbor Laboratory Press, 1989 (TOC). [cited by applicant]
Saitou, Naruya , et al., “The neighbor-joining method: a new method for reconstructing phylogenetic trees”, Molecular Biology and Evolution, vol. 4, Issue 4, Jul. 1987, pp. 406-425, https://doi.org/10.1093/oxfordjournal… [cited by applicant]
Sneath, Peter H.A., et al., “Numerical Taxonomy—The Principles and Practice of Numerical Classification”, Nature 193, 855-860 (1962) W. H. Freeman and Co. (TOC). [cited by applicant]
Sun, Chuang , et al., “THEMIS-SHP1 Recruitment by 4-1BB Tunes LCKMediated Priming of Chimeric Antigen Receptor-Redirected T Cells”, Cancer Cell 37, 216-225; 202; Elsevier Inc.; https://doi.org/10.1016/j.ccell.2019.12.01… [cited by applicant]
Sunder-Plassmann, Raute , “Functional analysis of immunoreceptor tyrosinebased activation motif (1TAM)-mediated signal transduction: the two YxxL segments within a single CD3c-ITAM are functionally distinct”, Eur. J. Im… [cited by applicant]
Syrigos, Konstantinos , et al., “Antibody Directed Enzyme Prodrug Therapy (ADEPT): A Review of the Experimental and Clinical Considerations”, Review, Anticancer Research 19: 605-614 (1999). [cited by applicant]
Trail, Pamela A., et al., “Monoclonal antibody drug immunoconjugates for targeted treatment of cancer”, Symposium in Writing, Cancer Immunol Immunother (2003) 52: 328-337. [cited by applicant]
Vaughan, Tristan , et al., “Huinan Antibodies with Sub-nanon1olar Affinities Isolated fron1 a Large Non-In1n1unized Phage Display Library”, Nature Biotechnology, vol. 14 1996, 309-314. [cited by applicant]
Wilbur, W. J., et al., “Rapid Similarity Searches of Nucleic Acid and Protein Data Banks”, 1983, Proc. Natl. Acad. Sci. USA vol. 80, pp. 726-730. [cited by applicant]
Xu, Hua, et al. “A Kinase-Independent Function of Lck in Potentiating Antigen-Specific T Cell Activation”; Cell, vol. 74, 633-643, Aug. 27, 1993. [cited by applicant]